What is LightDeck Diagnostics?
Founded in 2009, LightDeck Diagnostics specializes in the development of advanced diagnostic technology designed to provide rapid, lab-quality results in a point-of-care setting. The company's core competency lies in its unique planar waveguide technology, which enables highly sensitive detection of pathogens and biomarkers. By bridging the gap between complex laboratory instrumentation and accessible, portable diagnostic tools, LightDeck has established itself as a vital contributor to public health and clinical diagnostics. Their market position is reinforced by a diverse portfolio of applications, ranging from infectious disease screening to complex protein analysis, serving both commercial healthcare providers and national security interests.
How much funding has LightDeck Diagnostics raised?
LightDeck Diagnostics has raised a total of $53.8M across 4 funding rounds:
Series A
$2M
Series B
$11M
Grant
$5.7M
Grant
$35.1M
Series A (2011): $2M, investors not publicly disclosed
Series B (2020): $11M led by Incubic, Boulder Ventures, and Entrada
Grant (2021): $5.7M supported by Biomedical Advanced Research and Development Authority
Grant (2021): $35.1M featuring U.S. Department of Defense
Key Investors in LightDeck Diagnostics
U.S. Department of Defense
The U.S. Department of Defense is a federal entity responsible for national security, frequently investing in advanced technologies and infrastructure to support military and public health readiness.
Boulder Ventures
Boulder Ventures is a venture capital firm specializing in early-stage IT and biotech investments, with a strong track record of supporting innovative companies in the Colorado region.
Biomedical Advanced Research and Development Authority
A federal agency focused on the advanced research and development of medical countermeasures to protect the nation from health security threats.
What's next for LightDeck Diagnostics?
Looking ahead, the strategic deployment of $35.1M is expected to catalyze the next phase of LightDeck Diagnostics' growth. With a strong foundation of government-backed research and development, the company is likely to focus on expanding its manufacturing capacity and broadening its regulatory approvals for new diagnostic assays. The integration of these funds will facilitate the scaling of their proprietary platform, enabling wider adoption across clinical and field-based environments. As the demand for rapid, reliable diagnostic data continues to rise globally, LightDeck is poised to leverage its technological edge to capture significant market share, potentially moving toward further commercialization and strategic partnerships that will solidify its status as a leader in the medtech industry.
See full LightDeck Diagnostics company page
